Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SHSE:600329 Voorraadrapport

Marktkapitalisatie: CN¥22.3b

Tianjin Pharmaceutical Da Ren Tang Group Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Tianjin Pharmaceutical Da Ren Tang Group has a total shareholder equity of CN¥6.5B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 19.8%. Its total assets and total liabilities are CN¥11.0B and CN¥4.5B respectively. Tianjin Pharmaceutical Da Ren Tang Group's EBIT is CN¥845.9M making its interest coverage ratio -3.2. It has cash and short-term investments of CN¥1.5B.

Belangrijke informatie

19.8%

Verhouding schuld/eigen vermogen

CN¥1.28b

Schuld

Rente dekkingsratio-3.2x
ContantCN¥1.45b
AandelenCN¥6.45b
Totaal verplichtingenCN¥4.52b
Totaal activaCN¥10.97b

Recente financiële gezondheidsupdates

Recent updates

Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Oct 27
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Oct 08
Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18
Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Analyse van de financiële positie

Kortlopende schulden: 600329's short term assets (CN¥7.1B) exceed its short term liabilities (CN¥4.2B).

Langlopende schulden: 600329's short term assets (CN¥7.1B) exceed its long term liabilities (CN¥323.7M).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 600329 has more cash than its total debt.

Schuld verminderen: 600329's debt to equity ratio has increased from 1.5% to 19.8% over the past 5 years.

Schuldendekking: 600329's debt is well covered by operating cash flow (91.8%).

Rentedekking: 600329 earns more interest than it pays, so coverage of interest payments is not a concern.


Balans


Ontdek gezonde bedrijven